Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy is an option for lung cancers harboring wild-type EGFR when chemotherapeutic reagents have failed. In this study, we found that the EGFR-TKI, gefitinib, modestly suppressed proliferation of the lung cancer cell lines, A549...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hua, Wang, Rong, Peng, Shunli, Chen, Longhua, Li, Qi, Wang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941313/
https://www.ncbi.nlm.nih.gov/pubmed/26919104
http://dx.doi.org/10.18632/oncotarget.7586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941313/
https://www.ncbi.nlm.nih.gov/pubmed/26919104
http://dx.doi.org/10.18632/oncotarget.7586

Ejemplares similares